Skip to content

Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence

Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence: Validation on Intention-to-treat Analysis of a IOUS-guided Approach

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02391207
Enrollment
50
Registered
2015-03-18
Start date
2009-01-31
Completion date
2014-12-31
Last updated
2015-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary Malignant Neoplasm of Liver

Brief summary

Major hepatectomies are generally selected for tumors involving the hepatic vein (HV) at the caval confluence (CC). As alternative, HV reconstruction has been proposed. The present study aimed to evaluate the feasibility and safety of a HV-sparing policy guided by intraoperative ultrasonography (IOUS) in a cohort of patients having at least one colorectal liver metastasis (CLM) in contact with a HV at CC. HV section can be avoided in the large majority of cases thanking to CLMs detachment or to HV partial resection or reconstruction: this policy seems feasible, safe, reduces the need of major hepatectomies, and oncologically provides an adequate local control.

Interventions

PROCEDUREHepatic vein-sparing hepatectomy

HV detachment, partial resection and section on the basis of HV-CLM relationship

Sponsors

University of Milan
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
28 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of at least one CLM in contact with HV at caval confluence and HV patency at preoperative imaging * at least 6 months of follow-up after surgery

Exclusion criteria

* suspected or ascertained thrombosis or full tumoral involvement of HV at preoperative imaging * portal pedicle infiltration and/or thrombosis * unresectability at laparotomy for any extra-hepatic or intrahepatic reason not related to tumor-vessel relations

Design outcomes

Primary

MeasureTime frame
the safety of HV-sparing surgery in terms of operative mortality and morbiditywithin 30-90 days after surgery

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026